Biogen Inc.
NASDAQ:BIIBDrug Manufacturers - General
-$2.21 today
- Market cap
- $37.16B
- Beta
- 0.18
- P/E (TTM)
- 21.1
- EPS (TTM)
- $9.32
Volume 1.14M
Average 1.17M
BIIB Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Biogen Inc.NASDAQ: BIIB
Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026
Capital expenditures turns positive
Q2 FY2026 capital expenditures was $40.9M, compared with -$16.6M a year earlier. Trailing-twelve-month capital expenditures was $89.8M. Over 3 fiscal years it compounded at -13.8% a year.
Context
- Capital expenditures amounted to 1.6% of revenue in FY2025, down 2.2 pp from a year earlier.
- Capital expenditures grew in size in 2 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly capital expenditures holds near $40.9M or moves back toward the trailing-twelve-month quarterly average of $22.45M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (153.8M) USD
- Year-over-year change
- +57.3%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (153.8M) | +57.3% |
| FY2024 | 2024-12-31 | (359.8M) | -15.5% |
| FY2023 | 2023-12-31 | (311.4M) | -29.6% |
| FY2022 | 2022-12-31 | (240.3M) | +6.9% |
| FY2021 | 2021-12-31 | (258.1M) | — |
Capital Expenditures vs competitors
How BIIB compares with its peers on the latest reported figures
- BIIB's LTM Jun 2026 capital expenditures of $89.8M is the 10th largest of the 11 companies compared; the peer median is $756.55M.
- Its year-over-year change of +134.5% is the 3rd highest of 11, against a peer median of +36.2%.
- Capital expenditures amounts to 0.9% of revenue for BIIB, versus a peer median of 6.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $8.03B | -26.9% | +38.0% | 10.1% | |
| LTM Sep 2026 | $4.01B | -28.0% | +31.9% | 6.5% | |
| LTM Jun 2026 | $2.42B | -12.1% | -6.7% | 3.8% | |
| LTM Jun 2026 | $2.3B | +63.6% | +25.7% | 6.0% | |
| LTM Jun 2026 | $920.9M | +2.4% | +15.0% | 5.9% | |
| LTM Jun 2026 | $592.2M | +97.2% | +55.4% | 18.8% | |
| LTM Jun 2026 | $496.8M | +43.3% | +28.8% | 3.9% | |
| LTM Jun 2026 | $302.05M | +1172.9% | +25.3% | 29.9% | |
| LTM Jun 2026 | $91.95M | +151.6% | -6.6% | 1.9% | |
| LTM Jun 2026 | $89.8M | +134.5% | -13.8% | 0.9% | |
| LTM Sep 2026 | $71.85M | +29.1% | +36.8% | 7.5% | |
| Peer median (excluding BIIB) | $756.55M | +36.2% | +27.2% | 6.2% | |
Competitors are the stored peer set for BIIB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 1.73B | 2.96B | 1.16B | 1.63B | 1.29B |
| Depreciation & Amortization | 487.7M | 518.4M | 494.8M | 673.2M | 779.9M |
| Deferred Income Tax | (426.8M) | (168.6M) | (305.8M) | (158.1M) | 361.6M |
| Stock-Based Compensation | 238.6M | 254.1M | 264.2M | 291.2M | 290.8M |
| Change in Working Capital | (145.5M) | (890.3M) | (648.7M) | (155.2M) | (1.06B) |
| Accounts Receivables | 326M | (222.4M) | 56.7M | 194.2M | 42.1M |
| Inventory | (462.4M) | (320.2M) | (130.9M) | (273.8M) | (64.7M) |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | (9.1M) | (347.7M) | (574.5M) | (75.6M) | (1.04B) |
| Other Non-Cash Items | 1.76B | (1.29B) | 581.2M | 592.2M | 537M |
| Operating Cash Flow | 3.64B | 1.38B | 1.55B | 2.88B | 2.2B |
| Capital Expenditures | (258.1M) | (240.3M) | (311.4M) | (359.8M) | (153.8M) |
| Acquisitions (Net) | 28.1M | 595M | (6.91B) | (1.07B) | 0 |
| Purchases of Investments | (3.81B) | (3.45B) | (5.14B) | 0 | (1.26B) |
| Sales of Investments | 3.5B | 4.66B | 8.29B | 551.5M | 79.7M |
| Other Investing Activities | 12.9M | 24.4M | (11.3M) | 83.9M | (38.7M) |
| Investing Cash Flow | (563.7M) | 1.59B | (4.09B) | (799.2M) | (1.37B) |
| Debt Repayment | (170M) | (1B) | 187.3M | (650M) | (16.9M) |
| Common Stock Issued | (700K) | (1.9M) | (44.3M) | (31.3M) | (10M) |
| Common Stock Repurchased | (1.8B) | (750M) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (115.5M) | (5.6M) | (6M) | (2.2M) | (275M) |
| Financing Cash Flow | (2.09B) | (1.76B) | 137M | (683.5M) | (301.9M) |
| Effect of Forex Changes | (59.8M) | (55.7M) | 35.1M | (67.7M) | 101.9M |
| Net Change in Cash | 930.2M | 1.16B | (2.37B) | 1.33B | 633.5M |
| Free Cash Flow | 3.38B | 1.14B | 1.24B | 2.52B | 2.05B |
Biogen Inc.
NASDAQ:BIIB
Intrinsic Alpha fair value
Locked
Current Price
$251.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.